Dynavax Technologies Corporation (DVAX) |
|
8.66 -0.52 (-5.66%)
|
07-10 16:00 |
|
Open: |
9.11 |
Pre. Close: |
9.18 |
|
High:
|
9.18 |
Low:
|
8.52 |
|
Volume:
|
4,027,874 |
Market Cap:
|
942M |
|
|
|
|
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Its immuno-oncology portfolio includes development stage products, such as SD-101 and DV281. Dynavax Technologies Corporation has a research collaboration with Clover Biopharmaceuticals; the University of Queensland and the Coalition for Epidemic Preparedness; and Sinovac Biotech Ltd. for the development of a vaccine candidate to prevent coronavirus (COVID-19). Dynavax Technologies Corporation has partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to create a vaccine against COVID-19 infection; and a collaboration with Valneva SE to initiate a vaccine program for the coronavirus, COVID-19. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
9.184 - 9.246 |
9.246 - 9.297 |
|
Low:
|
8.408 - 8.465 |
8.465 - 8.512 |
|
Close:
|
8.575 - 8.669 |
8.669 - 8.747 |
|
Technical analysis |
as of: 2020-07-10 4:27:07 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 11.40 One year: 13.31 |
| Support: |
Support1: 7.05 Support2: 5.38 |
| Resistance: |
Resistance1: 9.76 Resistance2: 11.40 |
| Pivot: |
8.29  |
| Moving Average: |
MA(5): 8.91 MA(20): 7.74
MA(100): 4.91 MA(250): 4.87 |
| MACD: |
MACD(12,26): 0.85 Signal(9): 0.82 |
| Stochastic oscillator: |
%K(14,3): 81.31 %D(3): 81.20 |
| RSI: |
RSI(14): 60.00 |
| 52-week: |
High: 9.76 Low: 1.80 Change(%): 114.4 |
| Average Vol(K): |
3-Month: 686756 10-Days: 695603 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.DVAX has closed below upper band by 39.2%. Bollinger Bands are 50.9% wider than normal. The large width of the bands suggest high volatility as compared to DVAX's normal range. The bands have been in this wide range for 10 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Fri, 10 Jul 2020
Dynavax Technologies Corporation (DVAX) Plunges 5.66% on July 10 - Equities.com
Wed, 08 Jul 2020
If You Had Bought Dynavax Technologies (NASDAQ:DVAX) Shares A Year Ago You'd Have Earned133% Returns - Yahoo Finance
Wed, 08 Jul 2020
Dynavax and Medicago Announce Collaboration to Develop a Novel Adjuvanted COVID-19 Vaccine Candidate - Yahoo Finance
Tue, 07 Jul 2020
Do Options Traders Know Something About Dynavax Technologies (DVAX) Stock We Don't? - Yahoo Finance
Sun, 05 Jul 2020
Is Dynavax Technologies Stock a Buy? - The Motley Fool
Thu, 02 Jul 2020
Dynavax Technologies Corporation (DVAX) Soars 4.33% on July 02 - Equities.com
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ Capital Market |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
109 |
| Shares Float (M) |
84 |
|
% Held by Insiders
|
1.15 |
|
% Held by Institutions
|
73.91 |
|
Shares Short (K)
|
12,580 |
|
Shares Short P. Month (K)
|
11,930 |
Stock Financials |
|
EPS
|
-1.780 |
|
EPS Est This Year
|
-1.630 |
|
EPS Est Next Year
|
-1.540 |
|
Book Value (p.s.)
|
0.140 |
|
Profit Margin
|
|
|
Operating Margin
|
-243.78 |
|
Return on Assets (ttm)
|
-22.1 |
|
Return on Equity (ttm)
|
-456.6 |
|
Qtrly Rev. Growth
|
89.1 |
|
Gross Profit (p.s.)
|
-0.343 |
|
Sales Per Share
|
0.371 |
|
EBITDA (p.s.)
|
-0.771 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-108 |
|
Levered Free Cash Flow (M)
|
-102 |
Stock Valuations |
|
PE Ratio
|
-4.87 |
|
PEG Ratio
|
|
|
Price to Book value
|
61.86 |
|
Price to Sales
|
23.34 |
|
Price to Cash Flow
|
-8.71 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
